Universal and Master Agreements

These agreements are available as starting points for negotiations with particular research sponsors for clinical and, in some cases, preclinical or other types of studies. Faculty members are welcomed to use these documents as starting points; however, all contracts must be processed through the appropriate office at each UT institution.

 

Abbott Laboratories - Diagnostic

 

Abbott Laboratories - Pharmaceuticals - Sponsored Clinical Study Agreement -   5/9/1994

 

Abbott Laboratories – Amended and Restated Master Clinical Study Agreement – Abbott Initiated – 3/26/2012

 

Abbott Laboratories - Master Clinical Study Agreement - Abbott Initiated - 12/7/2006

Adria - Research Agreement

 

Amgen, Inc. - Master Clinical Study Agreement for Phase I, II and III Studies Only - 12/27/2000 (UTMDACC, UTHSCHOU, UTMB, UTSMCDAL, UTHSCTY, UTHSCSA)

Amgen Master Materials and Funding Agreement - 6/8/2007

Army Research Laboratory (ARL) - Master Cooperative Research and Development Agreement (CRADA) – 5/30/2014

 

Astellas Pharma US, Inc. - Master Clinical Study Agreement - 4/18/2007

Astellas Pharma Global Development, Inc. – Amended and Restated Master Clinical Study Agreement – April 18, 2014

 

AstraZeneca Pharmaceuticals LP (AZPLP) - Clinical Trial Agreement (Sponsor Initiated, Effective February 1, 2006)

  • Note:  Please see Letter Agreementbetween University of Texas System and AstraZeneca, dated 2/14/2006.

Bayer - Clinical Trial Agreement - 12/1999

 

Biogen - Material Transfer Agreement - 6/24/1994

 

BoehringerIngelheim Pharmaceuticals, Inc. - Clinical Research Agreement - 7/13/1995

 

Bristol-Myers Squibb - Master Clinical Trial Agreement - 6/23/1998 (including Amendments #1, #2 and #3)

  • Amendment #1 effective 5/21/1999
  • Amendment #2 effective 7/2000
  • Amendment #3 effective 5/18/2001

California Biotechnology - Sponsored Research Agreement

 

DuPont Pharmaceuticals Company - Master Clinical Trial Agreement - 7/2000 (UTSMCDAL, UTHSCHOU, UTMB, UTHSCSA, UTMDACC, UTHSCTY)

 

Eli Lilly - Master Clinical Trial Agreement - 1/10/1995

  • Amendment #1 Effective 7/21/1998
  • Amendment #2 effective 12/14/1999
  • Amendment #3 effective 3/25/2002
  • Amendment #4 effective 12/12/2003
  • Amendment #5 effective 11/18/2004

Forest Research Institute - Amended and Restated Research Agreement - (Effective 1/1/2011 - 12/31/2017)

 

Fujisawa - Research and Study Agreement

 

Genentech - Clinical Research Agreement

 

Genzyme - Master Clinical Study Agreement - 4/6/2010

 

GlaxoSmithKline (GSK) - Master Clinical Study Agreement - 11/10/2003

Hoffmann-La Roche - Master Clinical Trial Agreement - 3/16/2009

Hoffmann-La Roche - Preclinical Lab Study Grant Agreement - Sponsor IND - 8/30/1994

 

Hoffmann-LaRoche - Preclinical Lab Study Grant Agreement - Funded Institutional IND- 2/14/1996

 

ICI Americas/Zeneca Pharmaceuticals - See Zeneca Pharmaceuticals

 

Integrated Therapeutics Group, Inc. - Clinical Trial Research Agreement - 8/2004

 

InterMune, Inc. - Clinical Study Agreement - 1/2005

 

Janssen Pharmaceutica Inc.- Clinical Study Agreement - 4/1995

 

Marion Merrell Dow - Non-Governmental Clinical Study Agreement - 2/2/1994

 

Matrix - Clinical Research Agreement

 

Merck & Co. - Clinical Study Agreement - 6/15/1995

 

NeoPharm, Inc. - Master Clinical Trial Agreement for Sponsor-Initiated Studies Only - 12/2002

 

Novartis Pharmaceuticals Corporation - Master Clinical Trial Agreement – Sponsor-Initiated

  • Effective 9/1/1998 through 8/31/2003
  • Amendment #1 (extends term: Effective 9/1/2003 thorugh 12/31/2003)

Novartis Pharmaceuticals Corporation - Master Clinical Trial Agreement – Sponsor-Initiated

Novartis Pharmaceuticals Corporation - Master Clinical Trial Agreement – Sponsor-Initiated

Organon Incorporated - Clinical Trail Agreement - 6/14/1995

 

Pfizer - Master Clinical Study Agreement (Sponsor Initiated) - 9/1/2008

 

Pfizer - Master Investigator-Initiated Research Grant Agreement - 6/1/2010

 

Pfizer - Master Program and Gift Agreement - 2/25/2008

 

Pfizer - Connecticut - Statement of Agreement - Clinical Study

 

Pfizer - New York - Clinical Study Agreement - Pfizer Initiated Study - 6/12/2003

 

Pfizer - New York - Clinical Study Agreement - 1/5/1995

 

Pharmacyclics, Inc. - Master Clinical Study Agreement - 3/9/2001 (UTHSCHOU, UTMB, UTHSCTY, UTSMCDAL, UTMDACC, UTHSCSA)

 

Schering Plough Research Institute - Investigator Initiated Master Clinical Trial Research Agreement - 7/1/2004

 

Schering-Plough Research Institute - Master Clinical Trial Agreement - 6/15/2009

 

Statewide Clinical Trials Network (CTNeT) – Master Clinical Trial Agreement – 8/15/2012

 

Syntex U.S.A. LLC - See Roche Palo Alto LLC

 

UCB Biosciences - Master Clinical Trial Agreement - 8/13/2013


U. S. Department of Veterans Affairs - Interinstitutional Cooperative Technology Administrative Agreement -  2/14/2002

 

University Hospital Consortium - Clinical Trial Research Agreement -  4/21/1993

 

Upjohn - Non-Governmental Clinical Study Agreement -  10/5/1993

 

Warner-Lambert Company - Non-Governmental Clinical Trial Agreement - 8/1998

 

Wyeth Pharmaceuticals, Inc. - Master Clinical Study Agreement -   7/22/2003

Xoma - Clinical Research Agreement

 

 

Most of the master contracts specific to a particular UT institution are not available online. Contact BethLynn Maxwell in OGC for copies of standard contracts specific to UT institutions.

 

 

 

Disclaimer: The materials on this website do not constitute legal advice. You should consult with an attorney before acting on or conveying any interpretation of these materials.

  • © The University of Texas System
  • Office of General Counsel
  • 201 West 7th Street
  • Austin, TX 78701
  • Phone: 512.499.4462
  • Fax: 512.499.4523
  •